Question 1

What side effects do GLP-1 medicines share?

Accepted Answer

The one thing every medicine in this class has in common is the gut. A 2022 review of newer diabetes medicines states that incretin mimetics often induce gastrointestinal side effects. Incretin mimetics are the wider family these medicines belong to, and gastrointestinal means the stomach and the bowel. A 2025 comparative review of semaglutide and tirzepatide reports that both showed digestive problems, including nausea, vomiting, pancreatitis and diarrhoea. A 2025 review of real-world use adds that observational studies suggest frequent digestive disturbance in people taking these medicines, as also seen in the trials. Nausea, vomiting and diarrhoea are the shared floor of this class rather than a quirk of one molecule. The rates differ by compound and by the trial that produced them, so those counts sit on the page for each compound.

Question 2

Which GLP-1 has the worst side effects?

Accepted Answer

No trial we could find was designed to settle this question. A 2026 pooled analysis of weight-loss medicines states that head-to-head comparisons of all three of these interventions are lacking. The three medicines are semaglutide, liraglutide and tirzepatide, and no trial among the research behind this page has measured them against each other directly. What exists instead is indirect comparison. That analysis pooled six of the 42 trials it screened, and found that all interventions had a comparable safety profile. A 2024 pooled analysis of 28 trials in 23,622 patients with type 2 diabetes found that both tirzepatide and semaglutide increased digestive side effects against placebo. Neither raised the risk of serious harm or of severe low blood sugar. So the published evidence does not separate the members of this class on harm. A rate for a single compound belongs on the page for that compound, rather than in a class ranking this evidence cannot carry.

Question 3

Which GLP-1 has the fewest side effects?

Accepted Answer

One review does state a preference, and it is worth reading closely. The 2025 comparative review concludes that tirzepatide was preferred over the commonly used single GLP-1 receptor agonists, because it had fewer reported side effects, along with effects on bone formation and on the kidney. That is a reading of post-marketing reports by its authors rather than a result measured in a trial built to compare. The 2026 network meta-analysis, which did pool randomised trials, reported a comparable safety profile across the three medicines it examined. Both groups were careful, they read overlapping evidence, and they landed in different places. We are not going to rank the members of this class on harm. The trial that would support such a ranking has not been published, and the two readings above are the reason that gap is worth stating plainly.

Question 4

Do GLP-1 medicines cause pancreatitis or thyroid cancer?

Accepted Answer

This is the question that brings most people to a safety page, and the class-level answer is softer than either side of the argument online. The 2025 real-world review reports no clear increase in risks of severe events like pancreatitis or pancreatic cancer, thyroid disorders, or depression and self-harm. Those are observational findings rather than trial findings. A 2019 meta-analysis of cardiovascular outcome trials treated severe low blood sugar, pancreatitis and pancreatic cancer as its named safety outcomes, which is how seriously the question was taken in patients with type 2 diabetes. Against that, the 2025 comparative review records that bone remodelling, kidney and thyroid disorders were detected after marketing. Observational data can miss a rare harm, and a reporting system can suggest one that is not there. That is why the two readings sit side by side rather than cancelling out.

Question 5

What do adverse-event reports show that the trials do not?

Accepted Answer

A 2025 analysis went to the FDA's own reporting system rather than to a trial. It searched the Adverse Event Reporting System for events linked to exenatide, liraglutide, dulaglutide, semaglutide and tirzepatide, from one year after each approval to the end of 2023. Across those five medicines it counted 9,746 reported adverse events. Medullary and papillary thyroid carcinoma carried the highest signals and were significant in virtually all of them. Next came reflux, the backflow of stomach acid into the gullet, which was significant in every medicine assessed. Read what that system is before reading the result. Anyone may file a report, nobody verifies it, and no one counts the people who took a medicine and had nothing happen. A signal there means the reports are out of proportion rather than that a medicine caused the event, which is why the authors call for monitoring and not for a conclusion.

Question 6

What are the long-term side effects?

Accepted Answer

This class is older than the attention it now gets. A 2019 pooled analysis gathered seven heart-outcome trials with 56 004 participants between them, and the medicines in them included exenatide, liraglutide, dulaglutide and both forms of semaglutide. Those trials ran for years, yet they were designed to count heart attacks and strokes rather than to follow the slower questions about this class. A 2025 review set out to look at post-marketing concerns about the long-term safety of these medicines, which is a sign of how much of the question sits outside the trial record. The 2025 real-world review names the open edge precisely: more evidence is needed on possible links with eye disease and other rare outcomes. Years of exposure inside a trial describe the people enrolled in that trial rather than everyone now holding an injector pen.

Question 7

What does a GLP-1 do to lean mass and bone?

Accepted Answer

Weight coming off is not only fat. A 2025 network meta-analysis of 22 randomised trials in 2,258 participants found that lean mass loss came to roughly a quarter of the total weight lost on these medicines. Lean mass is everything that is not fat, muscle included. The same analysis adds that relative lean mass, measured as a percentage change from where people started, was unaffected. Both sentences are true at once: people lost muscle, and they lost it roughly in step with everything else. Bone has one direct reading in this class. In a randomised trial in adults with obesity, liraglutide alone reduced bone mineral density at clinically relevant sites more than exercise alone, despite a similar amount of weight lost. Bone mineral density is the scan measure of how much mineral a bone holds, and that result is about one molecule used by itself.

Question 8

Do the GLP-1 pills have different side effects?

Accepted Answer

Two kinds of pill exist in this class: a tablet version of a peptide, and small molecules designed from the start to be swallowed. Both report the same family of problems. The PIONEER 1 trial of oral semaglutide, in 703 patients with type 2 diabetes, concluded that it carried a safety profile consistent with other GLP-1 receptor agonists. A 2023 trial of the oral small molecule orforglipron, in 272 adults, found its most common adverse events were digestive, mild to moderate, and clustered in the weeks when the amount was being stepped up. A 2025 phase 3 trial of the same compound in 3,127 patients reported an adverse-event profile consistent with that of other GLP-1 receptor agonists. Swallowing a medicine instead of injecting it changes the route, and on the published record it does not change the kind of side effect that follows.

Question 9

Are GLP-1 patches safe to use?

Accepted Answer

No study among the research behind this page has tested a patch, and no patch version of any GLP-1 medicine appears in it. What the record does cover is two routes into the body. In one phase 1 trial, patients with type 2 diabetes were randomly assigned to receive tirzepatide, semaglutide or placebo under the skin once per week. The other route is the mouth: oral semaglutide was the first GLP-1 receptor agonist made as a tablet, and orforglipron was tested as a once-daily oral therapy for weight reduction in adults with obesity. That distinction matters more than it sounds. An injected or swallowed peptide has a measured absorption path behind it, documented in the trials above, while a transdermal patch sold online has none of that. Everything counted on this page belongs to the injected and swallowed forms rather than to a patch.

Question 10

Does a larger amount cause worse side effects?

Accepted Answer

It did in the trials, and that is one of the steadiest patterns in this class. A 2022 meta-analysis of seven trials in 6,609 participants found nausea more frequent with tirzepatide than with placebo, most of all at the highest amount tested, with vomiting and diarrhoea rising alongside it. Timing matters as much as size does. In the orforglipron trial, gastrointestinal events occurred primarily during dose escalation, meaning the weeks when the amount is being raised rather than held steady. The real-world review found the far end of the same pattern, reporting the use of much lower doses than those evaluated in clinical trials. Put together, the documented side effects track both the amount administered and the speed of the escalation. That is a pattern observed in trials rather than a schedule that transfers to an unlabelled vial, and no part of this page turns it into one.

Question 11

Why do so many people stop taking them?

Accepted Answer

Stopping is the most common outcome in this class outside a trial, and the figures are not marginal. The 2025 real-world review reports high discontinuation rates of 20% to 50% within the first year. It names the reasons as well. Nausea and digestive problems are the main reasons patients stop, and cost is the other, with many people discontinuing within the first year because of side effects or the price. In the orforglipron trial, gastrointestinal events led to discontinuation in 10 to 17% of participants across the dose groups. That distance between a controlled trial and a kitchen cupboard may be the most useful figure on this page. A published adverse-event rate describes the participants who stayed enrolled, while the discontinuation rate describes everyone who did not, and the two answer different questions about the same medicine.

Question 12

Who was left out of the trials?

Accepted Answer

Every rate on this page belongs to the people who were enrolled, and they were a narrow group. The 2022 tirzepatide meta-analysis states its own limit, saying its findings generalise mainly to individuals who are overweight or obese and already on metformin-based background therapy. The 2026 network meta-analysis compared its three medicines in adults without type 2 diabetes who had obesity, or overweight with at least one obesity-related complication. Entry criteria that tight leave out most of the people now asking the question. Age is the sharpest edge of all. The one trial in young people randomly assigned 99 participants with a mean age of 14.7 years. Its primary endpoint was blood sugar measured at week 30, in youth-onset type 2 diabetes rather than in weight management. Older adults have no equivalent trial of their own in this class, so the published rates describe a middle band of age rather than the ends of it.

Question 13

What is known about combining a GLP-1 with something else?

Accepted Answer

Combination is where this class is heading, and the published safety record for it is thin and very specific. A phase 2 trial added efruxifermin, an experimental liver compound, to a steady GLP-1 regimen in 31 adults with liver disease and type 2 diabetes for 12 weeks. The most frequent related adverse events were mild to moderate digestive events, and there were no treatment-related serious adverse events. A 2017 review of pairing a GLP-1 receptor agonist with an SGLT2 inhibitor, a different class of diabetes medicine, argues that the two lower HbA1c by very different mechanisms. HbA1c is the three-month average of blood sugar. Exercise has the best-studied pairing of all. In a one-year randomised trial, adults with obesity were assigned to placebo, to supervised exercise, to liraglutide, or to exercise and liraglutide together. Everything outside those tested pairings is untested rather than cleared.

Question 14

Are compounded GLP-1 the same as the approved medicines?

Accepted Answer

No. The difference is a matter of regulation rather than chemistry. Everything on this page was measured on medicines a regulator has approved and labelled. The 2025 real-world review says as much, covering the approved weight-loss therapies in this class and naming liraglutide, semaglutide and tirzepatide. The randomised evidence behind the comparisons has the same shape: set amounts of named molecules, given to people who had to meet written entry rules. A compounded or research-grade vial has no label, no approved use and no record of its own. No study among the research behind this page has measured what is inside one. The numbers above belong to the approved medicines rather than to a vial that looks like them.

Question 15

What has not been studied across the class?

Accepted Answer

Three gaps matter more than the rest, and each one is named by the research itself. The first is rare harm and why people quit. The real-world review sets out ten areas of particular importance for further research, among them a better understanding of what drives early discontinuation. The second is food. A 2024 narrative review of what people eat on these medicines concludes that further research is needed on the nutritional needs of adults taking them, and on guidelines to support that. The third is the heart beyond the older molecules. A cardiovascular outcomes trial randomised 13,299 people at 640 sites in 30 countries to compare tirzepatide against dulaglutide, and that trial was fully recruited and ongoing when it was described. Until it reports, the heart evidence in this class belongs to the medicines that finished their own trials rather than to every member of the class.

GLP-1 side effects and safety data